A team of investigators report on their validated nomogram that incorporates pleural effusion into the classification of disease severity in patients with multiple myeloma.
Investigators sought to assess outcomes following CD19 CAR T-cell therapy in children and young adults who underwent alloHSCT for B-cell acute lymphoblastic leukemia.
Investigators deployed a survey to assess burnout, stress, emotional wellbeing, and pandemic experiences among pediatric hematology/oncology providers and staff.
The accelerated approval was based on data from the multicenter, open-label, phase 2 TROPHY study.
Among patients younger than 49 years, those with actinic keratosis had a nearly 7-times greater likelihood of developing cutaneous squamous cell carcinoma than patients without actinic keratosis.
A team of investigators assessed the frequency and timing of unplanned breast implant removal in patients undergoing with mastectomy, reconstruction, and postmastectomy radiation therapy for locally advanced breast cancer.
In current urological practice, clinicians decide whether to place a ureteral stent or nephrostomy, but evidence-based treatment guidance is needed.
A retrospective, single-center crossover study was conducted that compared rates of infection in patients with multiple myeloma during observation compared with those receiving IVIG.
Investigators conducted a study to determine the incidence and clinical course of BK virus hemorrhagic cystitis in children undergoing hematopoietic cell transplantation.
Researchers sought to determine whether adding ixazomib to treatment with lenalidomide plus dexamethasone would give a benefit to patients with newly diagnosed multiple myeloma.
Researchers sought to determine whether adding daratumumab to standard care for patients with multiple myeloma was a cost-effective option.
Tisotumab vedotin is an investigational antibody-drug conjugate targeted to tissue factor.
A team of investigators assessed the application of whole-genome sequencing for genomic profiling of patients with acute myeloid leukemia or myelodysplastic syndromes.
Investigators conducted a phase IIb study to assess the safety and efficacy of umbralisib 800 mg/d in patients with relapsed or refractory non-Hodgkin lymphoma.
Researchers compared clinical effectiveness and cost effectiveness of treatment regimens for multiple myeloma.
Researchers sought to determine whether rivaroxaban may be superior to low-molecular-weight heparin for reducing all-cause mortality.
Researchers sought to determine whether cambinol would have antitumor activity in multiple myeloma cells.
A study was conducted to assess factors contributing to response to nivolumab treatment for advanced clear cell renal cell carcinoma.
A retrospective study was conducted to identify the relationship between Alzheimer disease or other neurocognitive disorders and previous treatment with chemotherapy for colorectal cancer.
Investigators conducted a meta-analysis to determine if breathlessness is associated with shorter survival in patients with malignant pleural effusions.
An international, retrospective study was conducted to assess outcomes following alloHCT after PD-1 blockade in Hodgkin lymphoma.
A workshop was convened by the US Food and Drug Administration and the American Association for Cancer Research to create recommendations for trial design and later stages of drug development in multiple myeloma.
A single-arm, phase 2 trial was conducted to assess response to treatment with carfilzomib plus cyclophosphamide and dexamethasone among patients with relapsed/refractory multiple myeloma.
After a cancer diagnosis, male adolescents may be unprepared to make decisions about fertility preservation independently and instead need parental involvement.
Researchers hope their findings could lead to targeted interventions to improve cognitive outcomes in pediatric brain tumor survivors from families with low socioeconomic status.
Researchers sought to determine whether dasatinib and nilotinib would be effective second-line therapies for patients with chronic phase CML.
Researchers sought to determine the incidence and risk factors for acute kidney in patients with AML who are undergoing induction chemotherapy.
This schedule indicates the recommended age groups and medical indications for routine administration of currently licensed vaccines for persons 19 years and older.
A team of investigators sought to assess the impact of multimodality, CNS-directed treatments on survival rates in patients with melanoma brain metastasis.
A study was conducted to assess the safety and efficacy of fludarabine and cyclophosphamide combined with rituximab for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma in elderly patients and those with comorbid conditions.
A multicenter, randomized, phase 3 trial compared blinatumomab with intensive multidrug consolidation chemotherapy in children with high-risk, first-relapse B-cell ALL.
Researchers sought to determine whether molecular characteristics could help predict responses to treatments with venetoclax in patients with relapsed or refractory AML.
Oncologists and patients should be aware of the potential manifestations of the COVID-19 vaccination on imaging and the consequences this might have on disease assessment, treatment monitoring, and decision-making.
Investigators sought to determine the prevalence of weight gain and becoming overweight or obese and its association with hypothalamic-pituitary dysfunction in survivors of childhood brain cancer.
The Michigan Oncology Sequencing Program involved patients with advanced solid tumors who underwent next-generation sequencing to identify variants and potentially guide treatment.
Investigators sought to determine if docetaxel plus cisplatin maintenance therapy was effective among Asian patients with non-small cell lung cancer.
A list of contraindications and drug interactions for HIV medications.
Researchers sought to determine whether paroxysmal nocturnal hemoglobinuria clones might predict treatment responses for patients with MDS and aplastic anemia.
Investigators sought to evaluate the role of mean heart disease and left anterior descending dose in predicting the risk of major cardiac adverse events in patients with non-small cell lung cancer.
Researchers report findings from the double-blind, phase 3 CheckMate 451 trial of nivolumab plus ipilimumab, nivolumab monotherapy, or placebo in patients with extensive-disease small cell lung cancer.
Researchers describe the study results used to develop and validate a 4-item assessment score for predicting survival among older patients with hematologic cancers referred for chemotherapy.
Although the number of reported cases of SARS-CoV-2 infection among pediatric patients with cancer has been low, the effect of the pandemic on cancer care services for this population is not well understood.
Investigators conducted a retrospective study that included data from 145 patients who underwent treatment with nivolumab or pembrolizumab for advanced non-small cell lung cancer.
The COVID-19 pandemic sheds new light on existing access challenges in preventive health care.
Ajai Chari, MD, of Mount Sinai Hospital in New York City, provides his perspective on the current state of care in multiple myeloma.
Investigators conducted a study to determine if patients experienced delays in treatment for early-stage breast cancer as a result of the COVID-19 pandemic.
Semistructured interviews of patients and clinicians were conducted to explore how this disease affects the day-to-day lives of patients.
Researchers sought to determine whether R-MegaCHOEP would improve outcomes compared to R-CHOEP-14 in patients with newly diagnosed, aggressive B-cell lymphoma.
The approval is supported by data from the multicenter, randomized, open-label phase 3 IKEMA trial.
Seminal vesicle-sparing radical cystectomy improved functional results over a median of 64 months without compromising oncologic outcomes, according to investigators.
Investigators aimed to characterize the heterogeneity in PD-L1 expression among different histologic patterns of metastases of lung adenocarcinoma.
Investigators conducted a randomized controlled trial to determine whether the addition of ublituximab to treatment with ibrutinib improved outcomes in patients with relapsed or refractory chronic lymphocytic leukemia.
Investigators conducted an integrated analysis of phase 1 and 2 trials assessing the efficacy of entrectinib among patients with ROS1 fusion-positive non-small cell lung cancer
In this prospective study, researchers sought to determine the effect of mean muscle mass on clinical outcomes and survival among hospitalized patients with advanced cancer.
Researchers sought to see whether long-term results of a trial involving moxetumomab pasudotox would have durable response for patients with relapsed/refractory HCL.
Researchers reviewed patient samples to determine whether NGS of cell-free DNA may help in treatment decision-making for patients with hematologic malignancies who may have an infection.
High-risk NMIBC progression more than doubled healthcare costs over 5 years compared with no progression, a study found.
Ryzneuta, also known as F-627, is an investigational, recombinant fusion protein containing G-CSF at the amino terminal and human IgG2-Fc fragment at the carboxyl terminal.
Researchers sought to determine key determinants of sustained treatment-free remission in patients with CML who have completed TKI treatment in an attempt to develop strategies that achieve long-term remission.
A team of investigators conducted a randomized controlled trial to assess outcomes following salvage endoscopic surgery vs radiation therapy in patients with resectable, locally recurrent nasopharyngeal cancer.
Investigators assessed the association of aspirin, other nonsteroidal anti-inflammatory drugs, and statins with the risk of developing non-Hodgkin lymphoma.
This schedule indicates the recommended ages for routine administration of currently licensed childhood vaccines for children 0-18 years of age.
A team of researchers sought to evaluate the association between the Genomic Prostate Score and long-term outcomes in patients having undergone radical prostatectomy for prostate cancer.
A multicenter, phase 2 trial will assess the efficacy and safety of osimertinib among patients with isolated CNS or systemic progression of EGFR mutation-positive non-small cell lung cancer after treatment with an EGFR tyrosine kinase inhibitor.
A team of investigators created the myeloid index score, which captures the prognostic value of blood myeloid cells and may be used in the management of patients with melanoma.
A randomized trial sought to determine the effectiveness of electroacupuncture and auricular acupuncture in managing musculoskeletal pain in cancer survivors.
In a small phase 2 trial involving men with intermediate-risk prostate cancer, a single ultra-high dose of radiation was safe and comparable to curative hypofractionated stereotactic body radiation therapy in tumor control and quality-of-life measures.
Overall, Black and White men with metastatic castration-resistant prostate cancer had similar median overall survival times, according to a British study.
Robotic-assisted radical prostatectomy is associated with higher costs than open radical prostatectomy at the index hospitalization for the surgery, but it is associated with less healthcare use during the 1 year after discharge.
Abecma is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy.
A team of investigators sought to assess cardiac safety data associated with the use of doxorubicin in patients with soft tissue sarcomas.
A team of investigators conducted a retrospective study to assess outcomes with the use of chemotherapy in patients 80 years of age and older diagnosed with metastatic non-small cell lung cancer.
Results of an assessment of tissue composition changes experienced by breast cancer survivors without lymphedema are presented.
A team of investigators sought to determine if treatment efficacy can be maintained without radiotherapy among patients with newly diagnosed, early-stage, unfavorable Hodgkin lymphoma.
A case study with a literature review demonstrates potential antiviral effect of TKI therapy in patients with cancer and COVID-19.
Researchers sought to determine if immunotherapy including blinatumomab could improve disease-free survival for patients with B-cell ALL.
Researchers sought to describe a potential link between treatment with lenalidomide and development of B-cell ALL in patients with CLL.
The open-label, phase 3 TAHOE trial assessed outcomes in patients with previously treated, DLL3-high advanced or metastatic small lung cancer treated with rovalpituzumab tesirine or topotecan.
Myeloproliferative neoplasms (MPN) are a rare form of blood cancer. Though most people don’t know a lot about, approximately 20,000 people develop MPNs each year. Here are the basics you can explain to a concerned patient.
Results of a phase 3 randomized trial of the eRAPID online system for patients to self-report symptoms while undergoing cancer therapy are presented.
Progression-free, three-year overall survival similar for lenalidomide maintenance regimen without dexamethasone.
A team of international researchers sought to confirm a “dual pathway hypothesis” for the development of melanoma.
A team of investigators conducted a phase 2 trial to assess outcomes of hepatitis C virus and varicella zoster vaccination in patients with treatment-naive CLL or those on BTK inhibitor therapy.
A team of investigators sought to improve the rates of anticoagulation for high-risk patients after a quality improvement project that added pharmacy/hematology oversight to VTE risk assessment.
A single-center, retrospective cohort study was conducted to assess response to treatment and progression of disease in patients with severe lymphopenia undergoing treatment with immune checkpoint inhibitors for NSCLC.
A retrospective analysis sought to determine the effect of omitting premedications and use of a rapid infusion rate on infusion-related reactions in patients receiving daratumumab for multiple myeloma.
A team of investigators sought to identify the level of adherence to medical standards and its association with the recurrence rate of breast cancer.
A team of investigators aimed to determine the incremental breast cancer detection rates associated with conventional breast imaging techniques.
Locoregional treatment improved survival for patients with de novo stage IV breast cancer and bone only metastasis compared with systemic treatment.
A team of investigators sought to determine the significance of the immunologic aspects of the antitumor response and reported their findings at the 17th St. Gillen International Breast Cancer Conference 2021.
A team of researchers sought to assess outcomes related to hypofractionated whole breast radiation following breast-conserving surgery in women aged younger than 50 years.
Results from the phase 3 monarchE trial on the addition of abemaciclib to endocrine therapy in patients with early breast cancer were presented at the 17th St. Gillen International Breast Cancer Conference.
A team of investigators conducted a retrospective, population-based, matched-cohort study to assess outcomes in young women who were diagnosed with early-stage breast cancer.
A team of investigators assessed the efficacy of trastuzumab in early-stage breast cancer and presented their research at the 17th St. Gallen International Breast Cancer Conference 2021.
A team of investigators sought to evaluate safety, tolerability, and antitumor activity neoadjuvant niraparib for patients with localized breast cancer.
A team of investigators sought to identify the most accurate preoperative breast imaging technique for determining tumor size in individuals with early breast cancer.
A team of researches sought to assess the effectiveness of breast cancer surveillance among patients with BRCA1/2 mutations.
A team of investigators who conducted a meta-analysis to evaluate the safety and efficacy of tyrosine kinase inhibitors in patients with HER-2 positive breast cancer with brain metastases presented their findings at the 17th St. Gallen International Breast Cancer Conference.
A team of investigators conducted a meta-analysis to evaluate the efficacy and safety of dual HER2 blockade with a pertuzumab-based regimen in patients previously exposed to anti-HER2 treatment.
Final results of the ExteNET study were presented at the 17th St. Gallen International Breast Cancer Conference 2021.